About Us

Novaliq is transforming ocular therapeutics

Novaliq is an ophthalmic pharmaceutical company based in Heidelberg, Germany with an office in Cambridge, U.S.

Novaliq’s mission is to transform ocular therapeutics based on EyeSol®, the first and only water-free technology, enhancing the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs.

Novaliq has developed a tiered portfolio of differentiated products addressing the needs of eye patients:
NovaTears® which improves the signs and symptoms of dry eye disease (DED) is marketed under CE-approval in Australia/NewZealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm.

Clinical Development

Two prescription drugs are in late stage clinical development:

  • CyclASol®, an anti-inflammatory and immunomodulating drug for the treatment of DED with a demonstrated early onset of action and excellent tolerability, is evaluated in the pivotal ESSENCE phase 2b/3 study.
  • NOV03, the first drug addressing evaporative DED associated with meibomian gland dysfunction (MGD), is evaluated in the SEECASE phase 2 study. Results for both U.S. trials are anticipated in Q3 2018.

Start typing and press Enter to search